Naveed Sana, Faheem Hira, Shazlee Kashif, Ashraf Muhammad Shamvil
Sana Naveed, FCPS Department of Pediatric Hematology/Oncology, Indus Hospital and Health Network, Karachi, Pakistan.
Hira Faheem, FCPS Department of Pediatric Hematology/Oncology, Indus Hospital and Health Network, Karachi, Pakistan.
Pak J Med Sci. 2023 Nov-Dec;39(6):1830-1834. doi: 10.12669/pjms.39.6.7721.
To determine diagnostic accuracy of F-FDG PET - CT imaging in determining Bone marrow involvement in pediatric HL by taking bone marrow biopsy as standard.
This descriptive cross-sectional study was conducted in the from July 2021 to December 2022. Treatment naïve histologically proven pediatric HL patients of both gender and aged between two to 16 years with both F-FDG PET - CT and bone marrow biopsy imaging were included. Basic demographics such as age, gender, height, weight, as well as classification and staging of HL was obtained. Results were assessed by expert reviewers who were blinded to clinical outcome. Sensitivity, specificity, positive and negative predictive value, and diagnostic precision were assessed. The data was analyzed via SPSS 26.0.
Total 131 participants were included with a male predominance i.e. 104 (79.6%). The mean (±SD) age was 8.7 ± 3.4 years. The present study reported PET/CT to have a sensitivity, specificity diagnostic accuracy, PPV and NPV of 94.1%, 92%, 92%, 64% and 99% respectively.
Our findings support the idea that BMB should not be routinely conducted in all patients but rather can be reserved exclusively for patients with dubious 18F-FDG bone marrow findings, as this test has strong diagnostic potential for evaluating BMI involvement in HL.
以骨髓活检为标准，确定F-FDG PET-CT成像在诊断儿童霍奇金淋巴瘤（HL）骨髓受累情况时的诊断准确性。
本描述性横断面研究于2021年7月至2022年12月进行。纳入未经治疗、组织学确诊的2至16岁男女儿童HL患者，均进行了F-FDG PET-CT和骨髓活检成像。获取年龄、性别、身高、体重等基本人口统计学数据以及HL的分类和分期。由对临床结果不知情的专家评审员评估结果。评估敏感性、特异性、阳性和阴性预测值以及诊断精度。通过SPSS 26.0分析数据。
共纳入131名参与者，男性占主导，即104名（79.6%）。平均（±标准差）年龄为8.7±3.4岁。本研究报告PET/CT的敏感性、特异性、诊断准确性、阳性预测值和阴性预测值分别为94.1%、92%、92%、64%和99%。
我们的研究结果支持以下观点，即不应在所有患者中常规进行骨髓活检，而应仅保留给18F-FDG骨髓检查结果存疑的患者，因为该检查在评估HL骨髓受累方面具有很强的诊断潜力。
